

# CITATION REPORT

List of articles citing

**Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey**

**DOI: 10.1002/pds.4785**

**Pharmacoepidemiology and Drug Safety, 2019, 28, 1035-1044.**

**Source:** <https://exaly.com/paper-pdf/73057360/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1035-1044	2.6	7
7	Clinical and Regulatory Concerns of Biosimilars: A Review of Literature. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	13
6	Health technology assessment of biosimilars worldwide: a scoping review. <i>Health Research Policy and Systems</i> , <b>2020</b> , 18, 95	3.7	2
5	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. <i>Advances in Therapy</i> , <b>2020</b> , 37, 4491-4518	4.1	12
4	Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , <b>2021</b> , 10, 205	3	
3	Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?. <i>Cadernos De Saude Publica</i> , <b>2019</b> , 35, e00087219	3.2	1
2	The whole experience of public hospital physicians from several specialties with biopharmaceutical effectiveness, safety, adverse drug reactions and interchangeability: A qualitative study. <b>2022</b> , 7, 100162		
1	Risk Management Plan: An Expert Analysis of Changes to the EAEU Good Pharmacovigilance Practice Requirements for the Content and Submission of the Document. <b>2023</b> , 11, 30-37		0